Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

momapy: a Python library to work with molecular maps.

Bioinformatics (Oxford, England)·2026
Same author

Post-Acute Sequelae of COVID-19 (PASC) in Hospitalized and Ambulatory Patients: A Comparative Study.

Journal of clinical medicine·2026
Same author

Integrative analysis of the mouse cecal microbiome across diet, age, and weight in the diverse BXD population.

Microbiome·2026
Same author

Fibromuscular Dysplasia: Emerging Concepts Beyond the International Consensus.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Integrative Analysis on the Urinary Proteome of Diabetic Kidney Disease, with an Emphasis on Extracellular Matrix Proteins.

International journal of molecular sciences·2026
Same author

Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.

BJU international·2026
Same journal

A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer.

Cancer research communications·2026
Same journal

DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment.

Cancer research communications·2026
Same journal

Chemotherapy Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors & Management Patterns.

Cancer research communications·2026
Same journal

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same journal

Tumor-Associated Platelets Suppress T-Cell Function and Promote Immune Evasion in TNBC via the P-selectin/ P-selectin glycoprotein ligand-1 Pathway.

Cancer research communications·2026
Same journal

Development of Glypican-3-Targeting Antibody-Drug Conjugates for Hepatocellular Carcinoma Therapy.

Cancer research communications·2026
See all related articles
  1. Home
  3. Repurposing Amiodarone For Bladder Cancer Treatment.
  1. Home
  3. Repurposing Amiodarone For Bladder Cancer Treatment.

Related Experiment Video

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.7K

Repurposing Amiodarone for Bladder Cancer Treatment.

Francisco J Roa1, Maria Roubelakis2, Konstantinos Paschidis3

  • 1Medical University of Innsbruck, Innsbruck, Austria.

Cancer Research Communications
|May 12, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Amiodarone, an antiarrhythmic drug, shows promise for treating muscle-invasive bladder cancer (MIBC). This repurposed drug effectively reduced tumor growth in preclinical models, offering a new therapeutic avenue for bladder cancer patients.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K
Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
08:15

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

15.8K

Related Experiment Videos

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.7K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K
Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
08:15

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

15.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Repurposing

Background:

  • Muscle-invasive bladder cancer (MIBC) treatment relies on chemotherapy and surgery, but survival rates necessitate novel therapeutic strategies.
  • Drug repurposing offers a viable approach to identify new bladder cancer treatments from existing medications.
  • Previous in silico work identified compounds for nonmuscle-invasive bladder cancer (NMIBC); this study extends the approach to MIBC.

Purpose of the Study:

  • To identify and validate repurposed drugs with potential antitumor activity against muscle-invasive bladder cancer (MIBC).
  • To investigate the efficacy of amiodarone, an antiarrhythmic drug, in preclinical bladder cancer models.

Main Methods:

  • An in silico drug repurposing strategy was employed to predict compounds effective against MIBC.
  • The efficacy of predicted candidates, including amiodarone, was evaluated in vitro using bladder cancer cell lines (NMIBC and MIBC).
  • In vivo efficacy and toxicity were assessed using a xenograft MIBC mouse model.

    • Main Results:

    • Amiodarone demonstrated the most potent inhibition of cell viability, proliferation, and colony formation across bladder cancer cell lines, particularly in aggressive MIBC models.
    • Amiodarone induced cell death and inhibited the mTOR signaling pathway.
    • In vivo, amiodarone significantly reduced tumor growth in a xenograft MIBC mouse model without observable toxicity.

    Conclusions:

    • Amiodarone is a potential repurposed drug for bladder cancer treatment.
    • The findings suggest amiodarone's anticancer effects are partly mediated by mTOR pathway inhibition.
    • Amiodarone may be particularly effective for muscle-invasive bladder cancer (MIBC).